Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC

Marc S Ballas
Abraham Chachoua

Introduction
Lung cancer is the leading cause of cancer-related death worldwide. Nonsmall cell lung cancer (NSCLC) is the most frequent type of lung cancer, accounting for more than 80% of lung cancer cases. As NSCLC currently has a 5-year survival rate of less than 20%, there is clearly a need for the development of more effective therapies.

Standard first-line treatment options depend on disease and patient characteristics, and may include surgery, platinum-based doublet chemotherapy, and targeted therapies. However, surgical resection is only a curative option if diagnosis occurs at early stage I or stage II disease (Table 1). At times, surgery with or without radiation with a more limited curative potential is an option for selected stage III NSCLC patients. Chemotherapy with a platinum-based doublet regimen is currently first-line therapy for more advanced disease, but is associated with only modest clinical benefits at the cost of significant toxicities. Furthermore, studies have shown no survival benefit and decreased quality of life with chemotherapy combinations beyond 4–6 cycles. Thus, in an effort to overcome these limitations, recent research has focused on targeted therapy.
### Table 1 Staging of NSCLCa

<table>
<thead>
<tr>
<th>Stage</th>
<th>TNM*</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Occult carcinoma</td>
<td>Tx</td>
<td>Tumor that cannot be assessed or detected radiologically or bronchoscopically but is proven histopathologically</td>
</tr>
<tr>
<td>0</td>
<td>N0 M0</td>
<td>No regional node involvement</td>
</tr>
<tr>
<td>IA</td>
<td>T1a T1b N0 M0</td>
<td>Tumor ≤2 cm surrounded by lung or visceral pleura and involving lobar bronchus but not main bronchus</td>
</tr>
<tr>
<td></td>
<td>N0 M0</td>
<td>No regional node involvement</td>
</tr>
<tr>
<td>IB</td>
<td>T2a T2b N1 M0</td>
<td>Tumor &gt;3 cm but ≤5 cm involving main bronchus ≥2 cm from carina or presence of atelectasis or obstructive pneumonitis that extends to the hilar region and involving invading visceral pleura</td>
</tr>
<tr>
<td></td>
<td>N0 M0</td>
<td>No regional node involvement</td>
</tr>
<tr>
<td>IIA</td>
<td>T2a N1 M0 Or</td>
<td>Tumor &gt;3 cm but ≤5 cm involving main bronchus ≥2 cm from carina or presence of atelectasis or obstructive pneumonitis that extends to the hilar region and involving invading visceral pleura</td>
</tr>
<tr>
<td></td>
<td>N0 M0</td>
<td>No regional node involvement</td>
</tr>
<tr>
<td>IIB</td>
<td>T2b N1 M0 Or</td>
<td>Tumor &gt;5 cm but ≤7 cm involving main bronchus ≥2 cm from carina or presence of atelectasis or obstructive pneumonitis that extends to the hilar region and involving invading visceral pleura</td>
</tr>
<tr>
<td></td>
<td>N0 M0</td>
<td>No regional node involvement</td>
</tr>
<tr>
<td>IIIA</td>
<td>T1–T3 N1 M0 Or</td>
<td>Involvement of ipsilateral peribronchial or hilar nodes and intrapulmonary nodes</td>
</tr>
<tr>
<td></td>
<td>N0 M0</td>
<td>No distant metastases</td>
</tr>
</tbody>
</table>

(Continued)
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Stage</th>
<th>TNM*</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>Or</td>
<td>No distant metastases</td>
</tr>
<tr>
<td>T4</td>
<td></td>
<td>Tumor any size invading the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; or tumor with satellite tumor nodule(s) in a different lobe, ipsilateral to that of the primary tumor</td>
</tr>
<tr>
<td>N0–N1</td>
<td></td>
<td>No regional node involvement or involvement of ipsilateral peribronchial or hilar nodes and intrapulmonary nodes</td>
</tr>
<tr>
<td>M0</td>
<td></td>
<td>No distant metastases</td>
</tr>
<tr>
<td>IIIB</td>
<td>T1–T4</td>
<td>Involvement of contralateral mediastinal or hilar nodes and ipsilateral or contralateral scalene or supraclavicular nodes</td>
</tr>
<tr>
<td>N0–N1</td>
<td></td>
<td>No distant metastases</td>
</tr>
<tr>
<td>T4</td>
<td></td>
<td>Tumor any size invading the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; or tumor with satellite tumor nodule(s) in a different lobe, ipsilateral to that of the primary tumor</td>
</tr>
<tr>
<td>N2</td>
<td></td>
<td>Involvement of ipsilateral mediastinal or subcarinal nodes</td>
</tr>
<tr>
<td>M0</td>
<td></td>
<td>No distant metastases</td>
</tr>
<tr>
<td>IV</td>
<td>Tx–T4</td>
<td>Any T</td>
</tr>
<tr>
<td>N0–N3</td>
<td></td>
<td>Any N</td>
</tr>
<tr>
<td>M1a</td>
<td></td>
<td>Satellite tumor nodule(s) in contralateral lobe to that of primary tumor or tumors with malignant pleural or pericardial effusion</td>
</tr>
<tr>
<td>M1b</td>
<td></td>
<td>Distant metastases</td>
</tr>
</tbody>
</table>

Notes: *Based on the Seventh Edition of TNM Staging of Lung Tumors; however, trials referred to in this review article have followed either the current or previous staging system depending on the time of their conduct; †The TNM system is based on tumor status, nodal status, and metastatic disease; ‡Nx indicates regional lymph nodes that cannot be assessed.


Abbreviations: NSCLC, nonsmall cell lung cancer; TNM, tumor node metastasis.

therapies that may more selectively inhibit tumor cell growth while minimizing toxicity to healthy cells and tissue.

**Currently available targeted agents for NSCLC**

Currently approved targeted agents in NSCLC are limited to inhibition of the epidermal growth factor receptor (EGFR)9,10 and vascular endothelial growth factor (VEGF) signaling pathways.11 The EGFR family of receptor tyrosine kinases serve as mediators of cell signaling by extracellular growth factors, with binding of their ligands activating intracellular pathways that promote tumor growth and survival.12 An activating mutation in EGFR is observed in approximately 10% of unselected Western lung cancer patients and in a higher percentage of certain NSCLC subgroups, such as nonsmokers and those of Asian ethnicity.12 Reversible EGFR-targeting tyrosine kinase inhibitors such as gefitinib (Iressa®; AstraZeneca; Wilmington, DE) and erlotinib (Tarceva®; Genentech; South San Francisco, CA) inhibit EGFR signaling.

Initial Phase II results with gefitinib led to approval by the United States Food and Drug Administration (FDA) of this agent for NSCLC. These results showed overall objective response rates (ORR) of 19% (95% confidence interval [CI], 11.5–27.3) among 105 patients with stage III/IV NSCLC receiving a dose of 500 mg/day and 18.4% (95% CI, 12.1–27.9) of 103 patients receiving 250 mg/day in one study and 10.6% (95% CI, 6.0–16.8) with both doses in another study.13,14 However, addition of gefitinib to standard chemotherapy failed to prolong overall survival (OS) compared with chemotherapy alone in subsequent Phase III trials.15–17 Based on more recent Phase III data in which OS with gefitinib was noninferior or not significantly different to that obtained with docetaxel, a taxane,18 in patients with advanced or metastatic NSCLC who had been pretreated with platinum-based chemotherapy,19,20 the United States restricted treatment with gefitinib to patients who have previously benefited from it.10 However, in the European Union and Asia, gefitinib remains in use for NSCLC patients with EGFR-activating mutations.21

Erlotinib was approved in the United States in 2004 for the treatment of patients with locally advanced or metastatic NSCLC whose disease has progressed following at least one chemotherapy regimen22 based on prolongation of OS (6.7 versus 4.7 months for placebo; hazard ratio (HR), 0.70; 95% CI, 0.58–0.85; P < 0.001) in a double-blind Phase III trial, BR21, involving 731 patients with stage IIIB/IV NSCLC.23
Erlotinib was also recently approved for maintenance therapy in patients with locally advanced or metastatic NSCLC whose disease has not progressed after 4 cycles of platinum-based therapy,34 based on the SATURN trial. The SATURN Phase III trial (N=884) showed erlotinib prolonged progression-free survival (PFS) versus placebo irrespective of EGFR mutation status (12.3 versus 11.1 months; HR, 0.71; 95% CI, 0.62–0.82; \( P < 0.0001 \)).25

Response rates in the gefitinib and erlotinib Phase III studies that were conducted in nonselected populations were typically around 10%, meaning that for many patients, their tumors fail to respond to these agents.26–28 Those who do respond to treatment eventually develop resistance to EGFR tyrosine kinase inhibitors, due either to a secondary mutation in the EGFR gene or amplification of mesenchymal-epithelial transition factor (MET), another receptor tyrosine kinase.12,29

The VEGF pathway controls angiogenesis, a necessary step in tumor growth, metastasis, and malignancy.30 Formation of new vasculature is required for larger tumors to obtain nutrients and oxygen; otherwise, nutrient supply is limited by diffusion, slowing tumor growth.31 Indeed, tumor vascularization is a prognostic indicator of disease progression in various cancers, including NSCLC.32–34 Thus, as tumor growth is dependent on developing and maintaining this blood supply, antiangiogenic treatments might be expected to have antitumor activity.

Bevacizumab (Avastin®, Genentech) is a monoclonal antibody directed against VEGF that is currently approved in combination with carboplatin, a platinum agent, and paclitaxel, a taxane, as first-line treatment of unresected, locally advanced, recurrent or metastatic nonsquamous NSCLC.35 Bevacizumab is only available for patients whose tumors have nonsquamous histology and is not recommended for patients with hemorrhage or recent hemoptysis.11,36,37 These exclusions are based on evidence from Phase II and III clinical trials. An early Phase II study randomized 99 patients with advanced (stage IIIB/IV or recurrent) NSCLC to receive bevacizumab 7.5 mg/kg or 15 mg/kg plus carboplatin and paclitaxel or chemotherapy alone.36 Bevacizumab 15 mg/kg significantly prolonged time to disease progression (TTP) (7.4 versus 4.2 months with chemotherapy alone; HR, 0.57; \( P = 0.023 \)) and provided a higher response rate (31.5% of 34 patients versus 18.8% of 32 patients) and a modestly increased median OS (17.7 versus 14.9 months; \( P = 0.63 \)). With the lower dose of bevacizumab, TTP was 4.3 months, ORR was 28.1% of 32 patients, and OS was 11.6 months. However, fatal hemoptysis was observed in 4 of 66 patients (6%) receiving bevacizumab. The study also correlated squamous histology with an increased risk of serious pulmonary hemorrhage, as four out of six cases of life-threatening bleeding occurred in patients with squamous carcinomas.36

The Phase III Eastern Cooperative Oncology Group (ECOG) 4599 trial38 evaluated bevacizumab 15 mg/kg in combination with carboplatin and paclitaxel in 878 chemotherapy-naive patients. Patients with squamous histology, brain metastases, inadequate organ function, clinically significant hemoptysis, or ECOG performance status \( > 1 \) were excluded. The ORR was higher with bevacizumab (133 out of 381 patients, 35%) compared with carboplatin and paclitaxel alone (59 out of 392 patients, 15%; \( P < 0.001 \)). The addition of bevacizumab also prolonged median OS (12.3 versus 10.3 months; HR, 0.80; \( P = 0.003 \)) and PFS (6.2 versus 4.5 months; HR, 0.66; \( P < 0.001 \)) compared with chemotherapy alone. Grade \( \geq 3 \) (lowest possible grade of an adverse event is 1 [mild adverse event] and highest possible grade is 5 [death]) bleeding events were reported in 19 out of 427 patients receiving bevacizumab plus chemotherapy (4.4%), while eight patients (1.9%) experienced hemoptysis.38 Fifteen treatment-related deaths were observed in the bevacizumab arm compared with two deaths in the carboplatin plus paclitaxel alone arm (\( P < 0.001 \)), five of which were caused by hemorrhage. Evaluable patients receiving bevacizumab plus carboplatin and paclitaxel (n = 427) experienced higher rates of grade 4 neutropenia (25.5% versus 16.8% in 440 patients receiving carboplatin and paclitaxel alone; \( P = 0.002 \)) and thrombocytopenia (1.6% versus 0.2%; \( P = 0.04 \)) as well as grade 3 febrile neutropenia (4% versus 1.8%; \( P = 0.02 \)), grade 3–4 hyponatremia (3.5% versus 1.1%; \( P = 0.02 \)), grade 3–4 hypertension (6.8% versus 0.5%; \( P < 0.001 \)), grade 3 headache (0.5% versus 3%; \( P = 0.003 \)), grade 3 rash (2.3% versus 0.5%; \( P = 0.02 \)), and grade \( \geq 3 \) bleeding events (0.7% versus 4.4%; \( P < 0.001 \)).

In the similarly designed Phase III AVAiL trial, first-line treatment with bevacizumab 7.5 or 15 mg/kg in combination with cisplatin and gemcitabine versus cisplatin and gemcitabine alone was evaluated in 1043 patients with recurrent or advanced NSCLC.39 Bevacizumab prolonged PFS at both 7.5 mg/kg (6.7 versus 6.1 months for placebo; HR, 0.75; \( P = 0.003 \)) and 15 mg/kg (6.5 months; HR, 0.82; \( P = 0.03 \) versus placebo),39 but OS was not significantly different, possibly due to the high use of post-study second-line treatments.40 The incidence of pulmonary hemorrhage was only 1.5% with bevacizumab 7.5 mg/day (5 out of 330 patients) and 0.9% with bevacizumab 15 mg/kg (3 out of 329 patients).39 The rates of grade \( \geq 3 \) hypertension, vomiting, neutropenia, and bleeding were numerically higher in patients who received bevacizumab than in patients who did not.
Another Phase III trial, the ATLAS study, compared bevacizumab 15 mg/kg plus erlotinib with bevacizumab alone as a maintenance therapy after 4 cycles of combined treatment with bevacizumab and platinum-based doublet chemotherapy in 768 patients with advanced NSCLC. Patients with treated brain metastases and peripheral or extrathoracic squamous tumors were allowed to participate in this study. Preliminary efficacy results showed that the combination of erlotinib plus bevacizumab increased PFS (4.8 versus 3.7 months for bevacizumab alone; HR, 0.72; 95% CI, 0.59–0.88; \( P = 0.0012 \)) but did not significantly prolong OS (15.9 versus 13.9 months; HR, 0.90; \( P = 0.2686 \)). Safety data (n = 598) have been reported for the initial chemotherapy phase of the trial. The most common grade ≥3 adverse event was hypertension, reported for 13 out of 303 patients receiving bevacizumab with carboplatin and paclitaxel (4.3%), 9 out of 183 patients receiving bevacizumab with carboplatin and gemcitabine (4.9%), and 3 out of 112 receiving carboplatin plus docetaxel (2.7%). Grade ≥2 pulmonary or central nervous system hemorrhage each occurred in less than 2% of patients, as did grade ≥3 gastrointestinal perforations. Overall hemorrhage rates (all grades) were reported for seven patients (2.3%) with bevacizumab plus carboplatin and paclitaxel, nine patients (4.9%) with bevacizumab plus carboplatin and gemcitabine, and nine patients (8%) with carboplatin plus docetaxel.

The Phase II BRIDGE study examined whether paclitaxel and carboplatin in combination with delayed bevacizumab administration would improve tolerability in patients with previously untreated squamous NSCLC; out of 31 patients treated with bevacizumab, one patient (3.2%) experienced a grade 3 pulmonary hemorrhage. Ongoing follow-up Phase II and III trials are currently evaluating bevacizumab therapy in combination with other targeted agents as well as standard chemotherapy in both first-line and second-line settings for multiple malignancies, including NSCLC. While bevacizumab is the only antiangiogenic therapy currently approved for NSCLC, there are several other compounds currently in clinical development, including monoclonal antibodies to VEGF and inhibitors of the intracellular tyrosine kinase domain of the VEGF receptor, as described later in this review. Because of the issues of resistance and eligibility associated with currently approved targeted agents in NSCLC, there is a critical need for improved therapies. The subsequent sections of this review highlight important antiangiogenic targets as well as emerging clinical data regarding novel antiangiogenic compounds for NSCLC treatment.

### Rationale for targeting angiogenic pathways in NSCLC

#### VEGF signaling

Important proangiogenic targets for the development of antiangiogenic therapies include VEGF, fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF), along with their corresponding receptors (VEGFR, FGF, and PDGFR, respectively). The VEGF-related family of proangiogenic signaling factors comprises VEGF-A (commonly referred to as VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor (PIGF). In addition to tumor angiogenesis, VEGF signaling mediates several other pathological conditions including inflammatory disorders, female reproductive processes, and intraocular neovascularization syndromes. The VEGF ligands mediate their angiogenic effects via three receptor tyrosine kinases: VEGFR-1 (also known as fms-like tyrosine kinase 1 [flt-1]), VEGFR-2 (also known as kinase-insert domain receptor [KDR]), and VEGFR-3 (flt-4). The primary receptor for VEGF is VEGFR-2. Binding of VEGF to its receptors causes receptor dimerization, autophosphorylation, and downstream signaling through a variety of pathways, including phosphoinositide (PI)-3 kinase (PI3K), v-src sarcoma viral oncogene homolog (Src), and phospholipase-Cγ (PLCγ), which can activate proliferation and migratory pathways driving angiogenesis (Figure 1). Neuruplin-1 and neuropilin-2, members of the neuropilin family of receptors, are expressed on endothelial cells and may be activated by VEGF, dimerize with VEGFR-1 and -2, and activate downstream signaling; inhibitors of neuropilin-VEGF interaction are undergoing preclinical evaluation for the treatment of cancer. In animal tumor models, VEGF is produced both by tumor cells and also by stromal tissue, although stromal expression of VEGF was not observed in a study of NSCLC samples from patients. Upregulation of VEGF and VEGFR have been observed in NSCLC tumor samples, with expression correlated with tumor angiogenesis, shorter postoperative recurrence time, and shorter survival time.

A meta-analysis of NSCLC studies has also suggested that VEGF expression is an unfavorable prognostic factor for survival (HR, 1.48; 95% CI, 1.27–1.72). The FGF family comprises 22 ligands that have a diverse array of biological functions. For example, FGF signaling plays a role in fetal development; mutations in FGFRI are associated with bone disorders, and mutations in FGFR2 are known to cause various craniosynostosis syndromes.
Figure 1 Connections between VEGF/VEGFR signaling and angiogenic processes. Depiction of the role of VEGFR signaling in tumor angiogenesis.


Abbreviations: Akt, protein kinase B; BAD, Bcl-2-associated death promoter; cPLA, cytoplasmic phospholipase A; DAG, diacylglycerol; eNOS, endothelial nitric oxide synthase; ERK, extracellular signal-regulated kinase; FAK, focal adhesion kinase; HSP, heat shock protein; IP3, inositol trisphosphate; mAbs, monoclonal antibodies; MAPKAPK, mitogen-activated protein kinase-activated protein kinase; MEK, mitogen-activated protein kinase kinase; NOS, nitrous oxide synthase; P3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; PKC, protein kinase C; PLC, phospholipase C; Raf, v-raf 1 murine leukemia viral oncogene homolog 1; Ras, retrovirus-associated DNA sequences; TKIs, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
(premature closure of sutures in the fetal skull before completion of brain growth).\textsuperscript{57} FGF-1, FGF-2, FGF-4, FGF-5, and FGF-8 have been associated with angiogenesis.\textsuperscript{58} Two FGF receptor tyrosine kinases, FGFR-1 and FGFR-2, are expressed in endothelial cells and can activate signaling pathways involved in tumor angiogenesis including the PI3K and mitogen-activated protein kinase (MEK)–extracellular signal-regulated kinase kinase (ERK) pathways,\textsuperscript{58} resulting in endothelial cell activation and recruitment of pericytes, vascular smooth muscle cells, and monocytes.\textsuperscript{58,59} FGF also regulates expression of proteases, integrins, and cadherins involved in reorganization of the extracellular matrix.\textsuperscript{60,61} In this way, FGF signaling affects vascular integrity, an important component of the vascular remodeling required for angiogenesis.\textsuperscript{62} In addition, cross-talk between FGFs, VEGFs, and inflammatory cytokines and chemokines may play a role in the modulation of blood vessel growth in various pathological conditions, including tumors.\textsuperscript{58}

**PDGF signaling**

PDGF ligands are released from platelets upon vascular damage.\textsuperscript{63} There are five dimeric PDGF ligands, PDGF-AA, -BB, -CC, -DD, and -AB, and two receptor tyrosine kinases, PDGFR-α and PDGFR-β, which mediate downstream effects through some of the same pathways activated by VEGF (Figure 1).\textsuperscript{64} These receptors are expressed on endothelial cells, pericytes, and vascular smooth muscle cells,\textsuperscript{65} which aid in development of tumor microvessels. Release of PDGF-BB by endothelial cells recruits pericytes and vascular muscle cells, which, in turn, control vascular integrity, development, and stabilization.\textsuperscript{65–67} In a preclinical chorioallantoic membrane (CAM) model involving chick eggs, PDGF-AA, -AB, and -BB induced development of new blood vessels, while in another model, PDGF-BB but not -AA stimulated the migration of rat brain capillary endothelial cells.\textsuperscript{56,68} Enhanced PDGF signaling has been associated with tumorigenesis and angiogenesis, as well as other pathological events such as atherosclerosis and re-stenosis of vessels after balloon angiography and coronary artery bypass grafting.\textsuperscript{70} In addition, PDGF inhibition may be a rational strategy for treatment of fibrotic liver disease, pulmonary fibrosis, and the development of proliferative vitreoretinopathy.\textsuperscript{70}

The rationale for targeting the above signaling pathways arose from preclinical models, in which inhibition of VEGF/VEGFR, FGF/FGFR, or PDGF/PDGFR signaling resulted in reduced angiogenesis and impaired tumor proliferation. For example, treatment with a VEGF monoclonal antibody inhibited the growth of tumor cell lines that had been injected into nude mice, but did not affect the growth rate of the same cell lines in vitro, supporting the explanation that treatment was acting against angiogenesis rather than directly against tumor cells.\textsuperscript{71,72} Furthermore, activation of PDGF and FGF pathways has been implicated in the development of resistance to VEGF inhibition. In a mouse model of pancreatic cancer, relapse after treatment with an anti-VEGF monoclonal antibody was associated with tumor revascularization secondary to hypoxia-mediated induction of other proangiogenic factors, including increased FGF-2 expression.\textsuperscript{73} Upon combination treatment with both VEGF and FGF inhibitors, tumor revascularization and growth were reduced.\textsuperscript{73} Likewise, expression of PDGFR has also been associated with resistance to VEGF-targeted therapy in the mouse pancreatic cancer model, with combined targeting of VEGF and PDGF signaling producing regression of established tumor blood vessels and inhibiting tumor growth.\textsuperscript{74,75} In fact, the VEGF, PDGF, and FGF signaling pathways appear to be highly integrated, suggesting that compensation and/or synergism between pathways occurs in angiogenesis.\textsuperscript{76,77} Thus, targeting multiple receptor tyrosine kinases may be required for effective antiangiogenic therapies.

In the clinical development of antiangiogenic therapies, two approaches have been used (Table 2); the first has been to inhibit ligand binding and receptor activation using targeted antibodies, while the second has been to inhibit receptor activation using tyrosine kinase inhibitors targeting VEGFR, FGFR, and/or PDGFR. Results of Phase II and Phase III clinical trials of agents discussed in this review in NSCLC are summarized in Table 3.

**Investigational antiangiogenic agents for NSCLC**

**Investigational therapeutic antibodies**

Ramucirumab (IMC-1121B; ImClone Systems Inc, New York, NY) is a human monoclonal anti-VEGFR-2 antibody. In a Phase I study in which 37 patients with advanced solid malignancies were given escalating doses of ramucirumab, four patients (15%) had a partial response, and 11 patients (30%) exhibited a response or stable disease lasting 6 months or longer.\textsuperscript{78} The most common serious adverse events included hypertension (13.5%), abdominal pain (10.8%), anorexia, vomiting, alkaline phosphatase increases, headache, proteinuria, dyspnea, and deep vein thrombosis (each in 5.4% of patients). A dosage of 13 mg/kg was considered the maximum-tolerated dose in this study,
as two patients given the higher dose of 16 mg/kg experienced dose-limiting hypertension and deep venous thrombosis, respectively. Although none of the patients in this Phase I study had NSCLC, the findings provided the rationale for Phase II investigation of ramucirumab in this condition. A Phase II study is currently examining ramucirumab combined with paclitaxel and carboplatin as a first-line treatment for patients with NSCLC, including those with squamous histology or brain metastases, with a planned enrollment of approximately 40 patients. Preliminary results from 15 patients demonstrated an ORR of 67% (10 patients) with one complete response and a median PFS of 6 months. Two patients experienced serious adverse events (grade 2 pneumothorax and grade 4 febrile neutropenia), and one additional patient withdrew from the study due to pneumothorax.

### Investigational receptor tyrosine kinase inhibitors

Given the multitude of intracellular signaling pathways that influence tumorigenesis, a number of potential advantages may exist with agents that inhibit multiple targets simultaneously. For example, this approach may prevent the development of resistance to antitumor agents. In addition, using a multitargeted approach, multiple tumorigenic pathways (such as angiogenesis and cell survival) may be inhibited and so maximize antitumor activity.

BIBF 1120 (Boehringer Ingelheim, Ingelheim, Germany) is an orally available multitargeted TKI that inhibits signaling through VEGFR-1, -2, and -3, PDGFR-α/β, and FGFR-1, -2, and -3 as well as Src and flt-3. In preclinical models, including human tumor xenografts in nude mice and rat tumor models, BIBF 1120 reduced tumor vessel density and integrity, resulting in inhibition of tumor growth. In Phase I studies, the most common drug-related adverse events observed with BIBF 1120 were reversible serum liver enzyme elevations and mild fatigue. When BIBF 1120 was combined with pemetrexed, a folate antimetabolite, stable disease was achieved in 13 out of 26 patients (50%) with recurrent advanced NSCLC who had previously received one prior platinum-based chemotherapy regimen. In this study, grade 3 fatigue was reported by six patients (23%), and grade 3 increases in alanine transaminase (ALT) were observed in three patients (11%). In Phase I studies of BIBF 1120 monotherapy in patients with advanced solid tumors, the first study (N = 61) observed grade 3 liver enzyme elevations in three patients receiving once-daily dosing with BIBF 1120 and no patients receiving twice daily dosing, while the second study (N = 21) showed grade 3 elevations of ALT and γ-glutamyl transpeptidase (γ-GT) in six patients each and grade 3 elevation of aspartate aminotransferase (AST) in three patients.

A Phase II trial tested BIBF 1120 monotherapy in 73 patients with relapsed NSCLC for which one or two lines of chemotherapy had previously failed and who had an ECOG performance status of 0–2. Patients were assigned one of two doses: 150 mg (n = 37) or 250 mg (n = 36) twice daily. For all patients, median OS was 21.9 weeks, and median PFS was 6.9 weeks; one patient exhibited a partial response, and 48% of patients exhibited stable disease. Patients with an ECOG performance status of 0–1 (n = 56) exhibited a median PFS of 11.6 weeks and a median OS of 37.7 weeks. Grade 3 and 4 toxicities included ALT elevations (9.6%), diarrhea (8.2%), nausea (6.8%), γ-GT elevations (4.1%), abdominal pain (2.7%), vomiting (2.7%), anorexia (1.4%), AST

### Table 2 Approved and emerging antiangiogenic therapies for NSCLC

<table>
<thead>
<tr>
<th>Agent</th>
<th>Type</th>
<th>Target(s)</th>
<th>Current phase of clinical development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bevacizumab</td>
<td>Monoclonal antibody</td>
<td>VEGF</td>
<td>Approved for NSCLC</td>
</tr>
<tr>
<td>Ramucirumab</td>
<td>Monoclonal antibody</td>
<td>VEGFR-2</td>
<td>Phase III</td>
</tr>
<tr>
<td>Aflibercept</td>
<td>Fusion protein</td>
<td>VEGF</td>
<td>Phase III</td>
</tr>
<tr>
<td>BIBF 1120</td>
<td>TKI</td>
<td>VEGFR-1, -2, -3, PDGFR-α/β, FGFR-1, -2, -3, Src, flt-3</td>
<td>Phase III</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>TKI</td>
<td>VEGFR-2, -3, PDGFR-β, Raf, flt-3, c-kit</td>
<td>Phase III</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>TKI</td>
<td>VEGFR-1, -2, -3, PDGFR-α/β, c-kit, flt-3, RET</td>
<td>Phase III</td>
</tr>
<tr>
<td>Cediranib</td>
<td>TKI</td>
<td>VEGFR-1, -2, -3, PDGFR-β, FGFR-1, -2, -3, c-kit</td>
<td>Phase III</td>
</tr>
<tr>
<td>Motesanib</td>
<td>TKI</td>
<td>VEGFR-1, -2, -3, PDGFR-β, c-kit, RET</td>
<td>Phase III</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>TKI</td>
<td>VEGFR-1, -2, -3, PDGFR-α/β, flt-1, -3, c-kit</td>
<td>Phase III</td>
</tr>
<tr>
<td>Axitinib</td>
<td>TKI</td>
<td>VEGFR-1, -2, -3, PDGFR-β</td>
<td>Phase II</td>
</tr>
<tr>
<td>ABT-869</td>
<td>TKI</td>
<td>VEGFR-1, -2, -3, PDGFR-β</td>
<td>Phase II</td>
</tr>
</tbody>
</table>

**Abbreviations:** c-kit, stem cell factor receptor; FGFR, fibroblast growth factor receptor; flt-3, fms-like tyrosine kinase 3; NSCLC, non-small cell lung cancer; PDGFR, platelet-derived growth factor receptor; Raf, v-raf 1 murine leukemia viral oncogene homolog 1; ReT, rearranged during transfection receptor; Src, v-src sarcoma viral oncogene homolog; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
elevations (1.4%), and fatigue (1.4%). Phase III trials are currently testing BIBF 1120 in combination with docetaxel in the LUME-Lung 1 study (NCT00805194) and pemetrexed in the LUME-Lung 2 study (NCT00806819). Of note, the LUME-Lung 2 study only includes patients with NSCLC of nonsquamous histology to conform with the FDA-approved indication of pemetrexed.88

Other small molecule multitargeted tyrosine kinase inhibitors are currently in clinical development. Sorafenib (Bay 43-9006; Nexavar®, Bayer, Leverkusen, Germany) targets tumor cell growth and angiogenesis by inhibiting signaling through VEGFR-2 and -3, PDGFR-β, v-raf 1 murine leukemia viral oncogene homolog 1(Raf), flt-3, and stem cell factor receptor (c-kit).87 In a Phase II study of single-agent sorafenib in 51 patients with relapsed or refractory advanced nonsquamous NSCLC, there were no responses, but 30 patients (59%) exhibited stable disease.88 Median PFS was 2.7 months, while median OS was 6.7 months. The most common grade 3 and 4 adverse events included hypertension in two patients (4%) and hand-foot skin disease in five patients (10%). In a larger Phase II study involving 342 patients with pretreated NSCLC and no evidence of brain metastases, patients were treated with sorafenib for two cycles; patients who responded continued on sorafenib for the second stage of the study, patients with stable disease were randomized to sorafenib or placebo, and those with progression discontinued. Preliminary results from the 97 patients randomized in stage 2 of the study show that sorafenib treatment prolonged PFS to 3.6 months compared with 1.9 months with placebo (P = 0.01) and resulted in stable disease for 16 patients (29%) compared with two patients with placebo (5%; P = 0.002).89 The most common grade 3 or 4 adverse events were rash or hand-foot syndrome (15%) and fatigue (11%). Two patients receiving sorafenib in the first stage of the study and one patient in the second stage experienced grade ≥3 hemoptysis.

The Phase III ESCAPE trial evaluated sorafenib in combination with carboplatin plus paclitaxel in 926 patients with advanced untreated nonsquamous or squamous NSCLC,88 but the study was halted when an interim analysis showed median OS was 10.7 months with sorafenib plus chemotherapy and 10.6 months with chemotherapy alone (HR, 1.15; 95% CI, 0.94–1.41; P = 0.915). Likewise, there was no significant difference between treatments in PFS (4.6 versus 5.4 months, respectively; HR, 0.99, 95% CI, 0.84–1.16; P = 0.433) or ORR (27.4% versus 24.0%; P = 0.1015). Among patients with squamous histology, those receiving sorafenib (n = 109) had a lower OS (8.9 versus 13.7 months; HR, 1.85; 95% CI, 1.22–2.81) and PFS (4.3 versus 5.8 months; HR, 1.31; 95% CI, 0.94–1.83) compared with patients receiving chemotherapy alone (n = 114), whereas patients with other nonsquamous histologies had similar OS and PFS in the two treatment groups. The most common sorafenib-related grade ≥3 adverse events in all patients included rash (8%), hand-foot skin reaction (8%), and diarrhea (4%). The histological subtype of NSCLC did not appear to affect the overall tolerability of treatment; patients receiving sorafenib plus chemotherapy with nonsquamous versus squamous histologies had similar rates of drug-related adverse events occurring at all grades (77% versus 87%), grade 3 (26% versus 33%), and grade 4 (9% versus 9%), respectively. However, four out of six fatal hemorrhagic or bleeding events observed in this study (four with sorafenib and two with chemotherapy alone) occurred in patients with squamous histology (two in each arm).90 The results of the ESCAPE study led to the exclusion of patients with squamous histology from the subsequent NExUS trial, which aimed to compare first-line treatment with sorafenib in combination with gemcitabine and cisplatin versus gemcitabine and cisplatin alone in a planned 900 patients with advanced NSCLC (NCT00449033). However, the NExUS trial was also halted because it did not meet the primary endpoint for improving OS.91

Sunitinib (SU11248; Sutent®, Pfizer; New London, CT) targets signaling through VEGFR-1, -2, and -3, PDGFR-α/β, rearranged during transfection (RET), as well as c-kit and flt-3.92 Sunitinib single-agent therapy was investigated in a Phase II trial of 63 patients with advanced NSCLC that had progressed after platinum-based chemotherapy.93 Patients were excluded from this study if they had experienced a grade 3 hemorrhage or hemoptysis within 4 weeks before the start of the treatment; additionally, patients who had received prior antiangiogenic therapy were excluded. Seven patients achieved a partial response with sunitinib, resulting in an ORR of 11.1% (95% CI, 4.6–21.6), while 18 patients (28.6%) exhibited stable disease for ≥8 weeks. Median PFS was 12 weeks (95% CI, 10.0–16.1), median OS was 23.4 weeks (95% CI, 17.0–28.3), and the 1-year survival rate was 20.2% (95% CI, 10.0%–30.4%). The most common grade ≥3 adverse events were fatigue or asthenia in 18 patients (29%), lymphopenia in 15 patients (25%), pain or myalgia in 11 patients (14%), and dyspnea in seven patients (11%). Another second-line Phase II study of 47 patients with advanced NSCLC that had been treated with at least two chemotherapy regimens reported a partial response in one patient, giving an ORR of 2.1% (95% CI, 0.1–11.3), with 11 patients (23.4%) exhibiting stable disease for ≥8 weeks.94
Table 3 Results from Phase II and III trials of VEGF, FGF, and PDGF inhibitors in NSCLC

<table>
<thead>
<tr>
<th>Trial</th>
<th>Patient population</th>
<th>Treatment</th>
<th>RR</th>
<th>TTP</th>
<th>PFS</th>
<th>OS</th>
<th>Grade 3/4 AEs (≥5%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VEGFR-targeting agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase II, N = 99&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Untreated, advanced (stage IIIB/IV) or recurrent NSCLC; ECOG PS 0–2</td>
<td>Bevacizumab 15 mg/kg + C/P</td>
<td>31.5%</td>
<td>7.4 mo;</td>
<td>NR</td>
<td>17.7 mo</td>
<td>Leukopenia, 38%; thrombosis events, 15%; fever, headache, hypertension, infection, nausea, peripheral neuritis (each 6%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bevacizumab 7.5 mg/kg + C/P</td>
<td>28.1%</td>
<td>4.3 mo</td>
<td>11.6 mo</td>
<td></td>
<td>Leukopenia, 31%; diarrhea, 9%; hemoptysis, 9%; fever, hemorrhage, thrombotic events (each 6%)</td>
</tr>
<tr>
<td>E4599, Phase III, N = 878&lt;sup&gt;38&lt;/sup&gt;</td>
<td>Untreated, advanced (stage IIIB/IV) nonsquamous NSCLC; ECOG PS 0–1</td>
<td>Bevacizumab 15 mg/kg + C/P</td>
<td>35%</td>
<td>NR</td>
<td>6.2 mo; P &lt; 0.001</td>
<td>12.3 mo; P &lt; 0.001</td>
<td>Neutropenia, 25% (P = 0.002); febrile neutropenia, 5.2% (P = 0.02); hypertension, 7% (P &lt; 0.001)</td>
</tr>
<tr>
<td>AVAIL, Phase III, N = 1043&lt;sup&gt;39,40&lt;/sup&gt;</td>
<td>Untreated, advanced (stage IIIB/IV) or recurrent nonsquamous NSCLC; ECOG PS 0–1</td>
<td>Bevacizumab 15 mg/kg + C/G</td>
<td>30%</td>
<td>NR</td>
<td>6.5 mo; P = 0.03</td>
<td>&gt;13 mo in all arms</td>
<td>Neutropenia, 36%; thrombocytopenia, 23%; anemia, 10%; vomiting, 9%; hypertension, 9%; thrombotic events, 7%; asthenia, 5%</td>
</tr>
<tr>
<td></td>
<td>C/G</td>
<td></td>
<td>15%</td>
<td></td>
<td>4.5 mo</td>
<td>10.3 mo</td>
<td>Neutropenia, 17%; febrile neutropenia, 2%</td>
</tr>
<tr>
<td>Small molecule tyrosine kinase inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase II, N = 73&lt;sup&gt;35&lt;/sup&gt;</td>
<td>Advanced (stage IIIB/IV) relapsed NSCLC; ECOG PS 0–2 (ECOG PS 0–1; n = 56)</td>
<td>BiBF 1120 150 or 250 mg twice daily</td>
<td>1.4%</td>
<td>NR</td>
<td>6.9 wks (PS 0–2); 11.6 wks (PS 0–1)</td>
<td>21.9 wks (PS 0–2); 37.7 wks (PS 0–1)</td>
<td>ALT elevation, 9.6%; diarrhea, 8.2%; nausea, 6.8%</td>
</tr>
<tr>
<td>Phase II, N = 51&lt;sup&gt;38&lt;/sup&gt;</td>
<td>Relapsed or refractory advanced (stage IV) nonsquamous NSCLC; ECOG PS 0–2</td>
<td>Sorafenib 400 mg twice daily</td>
<td>0%</td>
<td>NR</td>
<td>2.7 mo</td>
<td>6.7 mo</td>
<td>Hand-foot skin reaction, 10%</td>
</tr>
<tr>
<td>Phase II, N = 342&lt;sup&gt;39&lt;/sup&gt;</td>
<td>NR; ECOG PS 0–1</td>
<td>Sorafenib 400 mg twice daily</td>
<td>0%</td>
<td>NR</td>
<td>3.6 mo; P = 0.01</td>
<td>NR</td>
<td>Hand-foot syndrome, 15%; fatigue, 11%</td>
</tr>
<tr>
<td>ESCAPE, Phase III, N = 926&lt;sup&gt;40&lt;/sup&gt;</td>
<td>First-line treatment, advanced (stage IIIB/IV) NSCLC; ECOG PS 0–1</td>
<td>Sorafenib 400 mg twice daily + C/P</td>
<td>27.4%</td>
<td>NR</td>
<td>4.6 mo</td>
<td>10.7 mo</td>
<td>Neutropenia, 9%; rash, 8% (P &lt; 0.001); hand-foot skin reaction, 8% (P &lt; 0.001); fatigue, 5%</td>
</tr>
<tr>
<td></td>
<td>C/P</td>
<td></td>
<td>24.0%</td>
<td></td>
<td>5.4 mo</td>
<td>10.6 mo</td>
<td>Neutropenia, 6%; rash, 1%; hand-foot skin reaction, 0%; fatigue, 2%</td>
</tr>
<tr>
<td>Phase II, N = 63&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Pretreated, advanced (stage IIIB/IV) NSCLC; ECOG PS 0–1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Sunitinib 50 mg/day</td>
<td>11.1%</td>
<td>NR</td>
<td>12 wks</td>
<td>23.4 wks</td>
<td>Fatigue/asthenia, 29%; lymphopenia, 25%; pain/myalgia, 17%; dyspnea, 11%; nausea/vomiting, 10%; dehydration, 8%; anorexia, headache, hypertension, neutropenia, thrombocytopenia (each 5%)</td>
</tr>
<tr>
<td>Phase II, (N = 47^a)</td>
<td>Pretreated, advanced (stage III/IV) NSCLC; ECOG PS 0–1</td>
<td>Sunitinib 37.5 mg/day</td>
<td>2.1% NR 11.9 wks</td>
<td>37.1 wks</td>
<td>Fatigue/asthenia, 17%; neutropenia, 8.7%; hypertension, 8.5%; dyspnea, 6.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------------------------------</td>
<td>---------------------</td>
<td>-----------------</td>
<td>------------</td>
<td>------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BR24, Phase III/III, (N = 296^b)</td>
<td>Untreated, advanced (stage III/IV) NSCLC; ECOG PS 0–1</td>
<td>Cediranib 30 mg/day + C/P ( P &lt; 0.0001)</td>
<td>38% NR 10.5 mo</td>
<td>11.9 wks</td>
<td>Neutropenia, 49%; fatigue, 29%; increased TSH, 27%; hypertension, 19%; diarrhea, 15%; dyspnea, 10%; anorexia, 6%; stomatitis, 6%; sensory neuropathy, 3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase II, (N = 35^c)</td>
<td>Preoperative, early stage (stage I/II) NSCLC; ECOG PS 0–1</td>
<td>Pazopanib 800 mg/day</td>
<td>n = 3 NR NR NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase II, (N = 32^d)</td>
<td>Pretreated, advanced (stage III/IV) or recurrent NSCLC; ECOG PS 0–1</td>
<td>Axitinib 5 mg twice daily</td>
<td>9% NR NR NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** PS is according to ECOG criteria; \(^a\)One patient had a PS of 2; \(^b\)One patient had an unknown PS.

**Abbreviations:** AE, adverse event; ALT, alanine transaminase; C/G, cisplatin/gemcitabine; C/P, carboplatin/paclitaxel; ECOG, Eastern Cooperative Oncology Group; FGF, fibroblast growth factor; mo, months; NR, not reported; NSCLC, nonsmall cell lung cancer; OS, overall survival; PFS, progression-free survival; PDGF, platelet-derived growth factor; PS, performance status; RR, response rate; TSH, thyroid-stimulating hormone; TTP, time to disease progression; veGF, vascular endothelial growth factor; veGFR, vascular endothelial growth factor receptor; wks, weeks.

<ref>Median PFS and OS were 11.9 weeks (95% CI, 8.6–14.1) and 37.1 weeks (95% CI, 31.1–69.7), respectively, while the 1-year survival rate was 84.4% (95% CI, 84.9–94.2). In common grade 3 adverse events, neutropenia, fatigue, and the 1-year survival rate was 38.5% (95% CI, 34.1–43.1); neutropenia was reported in the first 33 patients (9%).</ref>

<ref>ABT-869 (Abbott; Abbott Park, IL) inhibits signaling through VEGFR-1, -2, and -3, and PDGFR-\(\alpha/\beta\), and is being tested in an open-label randomized Phase II trial of patients with advanced NSCLC (NCT00693992). Patients with advanced NSCLC (NCT00693992) and 3-PDGFR-\(\alpha/\beta\), EGR-1, and ErbB2. Patients with uncontrolled disease were excluded from this study. Despite initial results from the Phase II interim analysis suggesting higher ORR with ABT-869 compared to placebo (16% vs. 2.1%), the study was halted due to lack of significant improvement in progression-free survival in the 3-PDGFR-\(\alpha/\beta\), EGR-1, and ErbB2 group. Median PFS was not significantly improved (6.5 months vs. 4.9 months, HR 1.31, P = 0.03).</ref>
Combination with carboplatin and paclitaxel. Preliminary results showed partial responses in 23% and 22% of patients in the 125 mg and 75 mg motesanib groups, respectively, with median PFS of 6.2 months among 89 evaluable patients; the most common grade 3 adverse events in the three groups were diarrhea (19%, 13%, and 3%), dehydration (17%, 8%, and 3%), fatigue (17%, 5%, and 8%), anorexia (12%, 2%, and 3%), and nausea (10%, 3%, and 2%). The ongoing Phase III MONET1 study (NCT00460317) was initially suspended because of a higher incidence of mortality and hemothysis in patients with squamous NSCLC treated with motesanib plus carboplatin and paclitaxel compared with those who had nonsquamous NSCLC. The trial has since resumed with an expected enrollment of 1400 patients, but recruitment is now limited to patients who have tumors with nonsquamous histology.

Pazopanib (GW786034; GlaxoSmithKline, London, UK) inhibits VEGFR-1, -2, and -3, PDGFR-β, c-kit, and RET, and inhibits VEGF-induced angiogenesis in tumor cell xenograft models. Motesanib is currently undergoing evaluation in patients with NSCLC in combination with chemotherapy. In an initial Phase Ib study involving 26 patients with solid tumors, grade ≥3 adverse events included hypertension (23% in the high-dose group), hand-foot syndrome (8% in the high-dose group), and fatigue (7% and 8% in the high- and low-dose groups, respectively).

Motesanib (AMG 706; Amgen, Thousand Oaks, CA) inhibits signaling through VEGFR-1, -2, and -3, PDGFR-β, c-kit, and RET, and inhibits VEGF-induced angiogenesis in tumor cell xenograft models. Motesanib is currently undergoing evaluation in patients with NSCLC in combination with chemotherapy. In an initial Phase Ib study involving 26 patients with solid tumors, grade ≥3 adverse events included hypertension (23% in the high-dose group), hand-foot syndrome (8% in the high-dose group), and fatigue (7% and 8% in the high- and low-dose groups, respectively).

Motesanib is currently undergoing evaluation in patients with NSCLC in combination with chemotherapy. In an initial Phase Ib study involving 26 patients with solid tumors, grade ≥3 adverse events included hypertension (23% in the high-dose group), hand-foot syndrome (8% in the high-dose group), and fatigue (7% and 8% in the high- and low-dose groups, respectively).

Motesanib is currently undergoing evaluation in patients with NSCLC in combination with chemotherapy. In an initial Phase Ib study involving 26 patients with solid tumors, grade ≥3 adverse events included hypertension (23% in the high-dose group), hand-foot syndrome (8% in the high-dose group), and fatigue (7% and 8% in the high- and low-dose groups, respectively). Motesanib is currently undergoing evaluation in patients with NSCLC in combination with chemotherapy. In an initial Phase Ib study involving 26 patients with solid tumors, grade ≥3 adverse events included hypertension (23% in the high-dose group), hand-foot syndrome (8% in the high-dose group), and fatigue (7% and 8% in the high- and low-dose groups, respectively). Motesanib is currently undergoing evaluation in patients with NSCLC in combination with chemotherapy. In an initial Phase Ib study involving 26 patients with solid tumors, grade ≥3 adverse events included hypertension (23% in the high-dose group), hand-foot syndrome (8% in the high-dose group), and fatigue (7% and 8% in the high- and low-dose groups, respectively). Motesanib is currently undergoing evaluation in patients with NSCLC in combination with chemotherapy. In an initial Phase Ib study involving 26 patients with solid tumors, grade ≥3 adverse events included hypertension (23% in the high-dose group), hand-foot syndrome (8% in the high-dose group), and fatigue (7% and 8% in the high- and low-dose groups, respectively).
promising, recently completed combination trials with TKIs have been disappointing. Nonetheless, results from ongoing studies are eagerly awaited to help determine how these new antiangiogenic agents may be best used either alone or in combination with traditional chemotherapy regimens to improve outcomes in individual patients.

Acknowledgments
This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc (BI PI). Writing and editorial assistance was provided by Robert Lee, PhD, of MedErgy, which was contracted by BI PI for these services. The authors received no compensation related to the development of the manuscript. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), were fully responsible for all content and editorial decisions, and were involved at all stages of manuscript development.

Dr Chachoua has served on the Speakers Bureau for Eli Lilly, Genentech, and Response Genetics, Inc. Dr Ballas has received past honoraria from Eli Lilly.

Disclosure
The authors report no conflicts of interest in this work.

References
10. Iressa® (gefitinib tablets) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
41. Kabbavenar FF, Miller VA, Johnson BE, O’Connor PG, Soh C, Tlas I. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol. 2010;28(15s): Abstract 7526.
86. Alinta® (pemetrexed disodium) [package insert]. Indianapolis, IN: Eli Lilly and Company; December 2009.


